Effect of Tadalafil on Erectile Dysfunction Treatment and QOL Improvement Effect (by SF-12) in Andropause Patients With Erectile Dysfunction

The Catholic University of Korea

Status and phase: Unknown; Phase 4

Conditions: Erectile Dysfunction; Andropause

Treatments: Drug: Tadalafil

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02943356

TEDQOL

Details and patient eligibility

About

Observational study to evaluate the effect of Tadalafil 5mg once daily on Erectile Dysfunction and QOL in Andropause patients with Erectile Dysfunction.

Patients will be observed for 8weeks.

Enrollment: 40 estimated patients

Sex: Male

Ages: 35+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Above 35 years men

2. Approving ADAM questionnaire and andropause patients with symptoms under contents

   ; easily fatigue, decreased sexual desire, general weakness, decreasing memory ect.

3. Patient with Erectile Dysfunction above 6 months

4. International Index of Erectile Function(IIEF-5) score under 21

5. Voluntarily one want to treatment with Tadalafil 5 mg daily

6. Voluntarily one agree this study and write informed consent

Exclusion criteria

1. Persons who have taken PDE-5 inhibitor within last one month for Erectile Dysfunction

2. Persons who taken testosterone treatment within last one month

3. Persons who be history of Myocardiac infarction

4. The history of taken organic nitrate drug

5. The history of cardiovascular disease

   • In myocardial infarction within the last 90 days was now
   • Unstable angina or angina pectoris during intercourse that occurred
   • New York Heart Association Class 2 during the last six months or more sever cardiac failure
   • Uncontrolled arrythmia, hypotension(<90/50mmHg), or uncontrolled blood pressure(>170/100mmHg)
   • Persons who have a stroke within the last six months

6. Persons who have degrative retinal disease including Pigmentary retinites

7. Formerly persons who have one eye blindness by Artery anterior ischemic optic neuropathy with or without taking PDE5 inhibitor.

8. Persons who use inhibitor or agonist drug f Hepatic cytochrome P4503A4

9. Persons who use alpha antagonist add antihypertensive drug

10. Moderate liver or kidney failure

11. Major psychiatric or personality disorder

12. Persons have phobia trial drug

13. Persons have invasive treatment of prostate gland

14. Congenital anomaly of penis

15. Galactose, Lactose, Glucose intolerance patient

16. Research coordinators who are deemed unfit

Trial design

Primary purpose: Supportive Care

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

Tadalafil

Experimental group

Description:

Patients will be treated with Tadalafil for 8 weeks.

Treatment:

Drug: Tadalafil